Salute e Benessere

Leqembi approved for the treatment of Alzheimer's disease in Hong Kong

Leqembi selectively binds to soluble amyloid-beta (Aβ) aggregates (protofibrils[4]), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques in AD, thereby reducing both Aβ protofibrils and Aβ plaques in the brain. Leqembi is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. Leqembi selectively binds to soluble amyloid-beta (Aβ) aggregates (protofibrils [4] ), as well...
PR Newswire
11/07/2024

Novo Nordisk receives Complete Response Letter in the US for once-weekly basal…

Bagsværd, Denmark, 10 July 2024– Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus. In the letter, the FDA has requests related to the manufacturing process and the type 1 diabetes indication before the review of the application can be completed. Novo Nordisk is evaluating the content of the CRL and...
Nasdaq GlobeNewswire
10/07/2024

Coagulation Factor Deficiency Market - US to Have the Lion's Share Among the…

Key Takeaways from the Coagulation Factor Deficiency Market Report Key Takeaways from the Coagulation Factor Deficiency Market Report Discover which therapies are expected to grab the major coagulation factor deficiency market share @ Coagulation Factor Deficiency Market Report Coagulation Factor Deficiency Overview Coagulation factor deficiency diseases, also referred to as bleeding or clotting disorders, encompass a range of inherited or acquired conditions marked by the...
PR Newswire
10/07/2024

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

PRESS RELEASE REGULATED INFORMATION 10 July 2024, 06:00 p.m. CESTSEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNTAND NEW NUMBER OF SHARESGhent, Belgium, 10 July 2024 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that in the context of the confirmation of the contribution in kind of the receivables outstanding under the...
Nasdaq GlobeNewswire
10/07/2024

LBB Specialties Announces Principal Partnership with Sudarshan

Sudarshan's pigment line, including the Prestige, Sumicos, Sumicair and Sudacos ranges, leverages advanced manufacturing processes and rigorous quality controls to produce pigments with exceptional color fidelity, stability and safety. This innovative range includes products that cater to the latest trends in color cosmetics, offering formulators versatile options for creating stunning and long-lasting makeup products. Sudarshan's pigment line, including the Prestige,Sumicos, Sumicair and...
PR Newswire
10/07/2024

Eligo Publishes in Nature a Landmark Study That Unlocks Genome Editing of…

"What Eligo has achieved shows that it's now possible to make specific changes to the DNA of bacteria in the gut, similar to how scientists have been editing human genes to investigate or treat genetic disorders," said David Bikard, cofounder of Eligo Bioscience and researcher at the Institut Pasteur in Paris. "What Eligo has achieved shows that it's now possible to make specific changes to the DNA of bacteria in the gut, similar to how scientists have been editing human genes to…
PR Newswire
10/07/2024

Medical Billing Market Evolution: From USD 16.8 Billion to USD 27.7 Billion |…

Browse in-depth TOC on "Medical Billing Market" Browse in-depth TOC on "Medical Billing Market" 360 - Tables48 - Figures300 - Pages Deployment Landscape The medical billing market is categorized into three deployment segments: cloud-based, on-premise, and SaaS-based solutions. As of 2023, the on-premise segment holds the largest market share. This preference is driven by healthcare institutions' stringent data security requirements and the need for customization...
PR Newswire
10/07/2024

PAP Devices Market to Be Worth $6.97 Billion by 2031- Exclusive Report by…

Positive airway pressure (PAP) devices pump air under pressure into the airway of the lungs. These devices prevent airways from collapsing, which may slow down breathing in people with respiratory problems such as obstructive sleep apnea. (OSA). Positive airway pressure (PAP) devices are used in hospitals, sleep clinics, and home healthcare settings to treat adult and pediatric or neonatal patients. Types of PAP devices include continuous positive airway pressure (CPAP) devices, bilevel positive…
PR Newswire
10/07/2024

Medical Spa Market Size to Hit USD 82.5 billion by 2034, at a 14.9% CAGR |…

The medical spa market is experiencing significant growth driven by a rising preference for medical aesthetics and a broader acceptance of cosmetic medical procedures. Medical spas operate under the supervision of licensed healthcare professionals, such as medical doctors, ensuring a higher standard of safety and efficacy compared to traditional spa settings. These establishments offer a unique blend of advanced aesthetic procedures and therapeutic services, combining the relaxing environment of…
PR Newswire
10/07/2024

Medical Case Management Market is projected to expand to USD 12.3 billion at a…

With the growing geriatric population across the world, the necessity to deliver better healthcare practices spurs. Geriatric healthcare management can consist of a wide range of medical assistance services. The growing preference for home care models is augmenting the size of the said ecosystem. Finance facilities, including banking services, medical assistance, and other legal activities can be facilitated using medical case management services. With the growing geriatric population across...
PR Newswire
10/07/2024

Recombinant Coagulation Factors Market to Be Worth $26.29 Billion by 2031 -…

Recombinant coagulation factors are glycoproteins produced by recombinant DNA technology. They are mainly used for the treatment of various coagulation disorders. They are gaining popularity due to their benefits, such as reduced risk of bloodborne disease transmission and effective treatment. Recombinant coagulation factors are glycoproteins produced by recombinant DNA technology. They are mainly used for the treatment of various coagulation disorders. They are gaining popularity due to…
PR Newswire
10/07/2024

FSH-free versus FSH-primed infertility treatment of women with polycystic ovary…

The number of matured oocytes after CAPA-IVM did not differ significantly between the non-FSH and FSH groups (13 [9; 18] vs. 14 [7; 18]; absolute difference –1 [95% confidence interval –5, 4]). There were also no significant between-group differences in other oocyte and embryology outcomes, including the number of cumulus-oocyte complexes, number of fertilized oocytes, total number of blastocysts and good blastocysts, and total number of frozen embryos. The live birth rate was 38.3% in the...
Nasdaq GlobeNewswire
10/07/2024

iHerb® Unveils New Global, Online Distribution Partnership with The Vitamin…

From supplements to skincare to grocery items, iHerb ships over 50,000 products from over 1,800 brands to more than 180 countries. With this partnership, health and wellness consumers can now access The Vitamin Shoppe's innovative range of premium brands, including The Vitamin Shoppe®, Vthrive The Vitamin Shoppe®, BodyTech®, and BodyTech® Elite, on iHerb's global, online platform. From supplements to skincare to grocery items, iHerb ships over 50,000 products from over 1,800 brands to more…
PR Newswire
10/07/2024

UPPAbaby Expands Innovation Footprint with 4moms Acquisition

"Acquiring 4moms marks a significant milestone for UPPAbaby as we continue our commitment to delivering exceptional products and experiences for parents," said Bob Monahan, CEO and Co-Founder of UPPAbaby. "4moms' expertise in innovation, design, and technology for in home products for growing families perfectly complements our 'Parenthood, Understood' brand mission. This acquisition will foster new opportunities for growth and collaboration, ensuring we remain at the forefront of…
PR Newswire
10/07/2024

XyloCor and SmartCella enter into license agreement for use of the Extroducer to…

XC001 is designed to reduce ischemic burden by creating new blood vessels in the heart through the local expression of multiple isoforms of vascular endothelial growth factor (VEGF). With the use of the Extroducer catheter, XyloCor can offer patients a better delivery option for local administration of XC001 directly to the heart, that is less invasive and eliminates potential risks associated with surgical administration. XC001 is designed to reduce ischemic burden by creating new blood...
PR Newswire
10/07/2024

Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of…

Skyhawk's SKY-0515 demonstrated dose-dependent huntingtin (HTT) mRNA reduction in healthy volunteers, with 72% reduction at the highest dose tested in the multiple ascending dose study SKY-0515 was generally well tolerated at all doses testedGiven these positive topline results, we anticipate dosing in the patient arm of the study in Q3 2024 and initiation of a Phase 2 study early next yearBOSTON, July10, 2024(GLOBE NEWSWIRE) --Skyhawk Therapeutics, Inc.,a clinical-stage...
Nasdaq GlobeNewswire
10/07/2024

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in…

Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represent potential co-primary endpoints to be explored in future trials LONDON and NEW YORK, July10, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative...
Nasdaq GlobeNewswire
10/07/2024

Industrial Bag Dust Filter Market to Grow at 4.7% CAGR, reaching $3.12 Billion…

Workers in heavy-duty sectors are exposed to dust and pollutants that are harmful to the body's respiratory system, which is a key factor driving the demand for industrial bag dust filters. Instances of respiratory issues among workers have been observed in the mining and cement sectors. Governments in several countries such as the United States, Canada, Japan, and others are imposing stringent regulations on these industries, covering environmental concerns, blasting activities, noise, and dust…
PR Newswire
10/07/2024

Clinical Trial Market Size is Expected to Grow at a CAGR of 4.3% and Overpass a…

Both governmental and private sponsorship of clinical trials is helping them increase in number. As the number of diseases and patients increases, there is more demand for research to come up with newer medicines and treatments. The rise in cancer patients is especially necessitating the development of more oncology clinical trials. Both governmental and private sponsorship of clinical trials is helping them increase in number. As the number of diseases and patients increases, there is more...
PR Newswire
10/07/2024

YewMaker - New Playbook Launches to Tackle Global Challenge of Wasted Medicines

Authored by Deloitte and YewMaker, this comprehensive report tackles the critical issue of medicines that are manufactured but never reach patients. Authored by Deloitte and YewMaker, this comprehensive report tackles the critical issue of medicines that are manufactured but never reach patients. Download the full report and start making a difference today : https://www.yewmaker.com/reducing-wasted-medicines-playbook The Crisis of Wasted Medicines Every year, billions of...
PR Newswire
10/07/2024

Orexo AB´s sustainability work ranked among top 5% by EcoVadis

It showcases the outcome of dedicated sustainability activities undertaken over the last several years across social, environmental and governance areas of Orexo AB. And it shows how the employees and partners are working together to achieve successes across four areas: Environment, Labor and Human Rights, Ethics and Sustainable Procurement. It showcases the outcome of dedicated sustainability activities undertaken over the last several years across social, environmental and governance areas of…
PR Newswire
10/07/2024

Nexstim Receives NBS System 5 Order from New European Customer

Press release, Helsinki, 10 July 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from New European Customer Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 through a distributor in Europe. The end customer is acquiring the system primarily for research purposes.The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. The NBS…
Nasdaq GlobeNewswire
10/07/2024

Essential Pharma launches campaign with International Health Partners to donate…

Essential Pharma launches campaign with International Health Partners to donate life-saving medicines to disaster-hit countriesDonations to help support over 30,000 patients in disaster-hit and vulnerable communities worldwide whilst reducing medicine wasteAntibiotics, cardiovascular and mental health drugs cover International Health Partners' (IHP's) signature programmes, maximising patient impactEgham, UK – 10 July, 2024– Essential Pharma, an international specialty pharma...
Nasdaq GlobeNewswire
10/07/2024

Crossject is awarded a 6.9 million euros financing from the French Government…

Key contribution to the acceleration of the development of ZENEO® EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French companies demonstrating outstanding growth and innovation potentialDijon, France, July 10 th, 2024 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the...
Nasdaq GlobeNewswire
10/07/2024
Altri  Comunicati